J&J/Janssen did not exercise option on Capricor (CAPR) Stem Cell Partnership

http://pipelinereview.com/index.php/2017070765181/DNA-RNA-and-Cells/Capricor-Therapeutics-Retains-Full-Rights-to-CAP-1002-as-Janssen-Biotech-Inc.-Decides-Not-to-Exercise-Option.html

Leave a Reply

Your email address will not be published. Required fields are marked *